ASP Isotopes, Inc. ASPI Seller Financed Portion Of Investment In East Coast Nuclear Pharmacy

Seller Financed Portion Of Investment In East Coast Nuclear Pharmacy at other companies

US Physical TherapyUSPH

$500K—

Global PartnersGLP

$5K-97.4%

PopularBPOP

$14.37M-6.2%

Douglas EmmettDEI

$0-100%

Acadia Realty TrustAKR

$11.32M—

Tractor Supply CompanyTSCO

$154.79M+82.7%

Other financials

Income statement

See full

Revenue$4.2M+279%

Gross profit$1.7M+409%

Operating income-$24.9M-213%

Net income-$7.1M+15.8%

EPS (diluted)-$0.06+50.0%

Balance sheet

See full

Cash & equivalents$211.7M+278%

Total debt$61.9M+1,787%

Total equity$289.0M+580%

Total assets$587.7M+547%

Cash flow

See full

Operating cash flow-$17.8M-460%

CapEx$6.1M+166%

Free cash flow-$23.9M-336%

Valuation

See full

Market cap$888.88M+25.9%

Enterprise value$739.08M+11.6%

P/S33×-127×

Profitability

See full

Gross margin17.6%-19.8pp

Operating margin-285.4%-102pp

Net margin-588.6%-112pp

FCF margin-244.6%-92.7pp

Returns & leverage

See full

Return on equity-95.6%-19.3pp

Debt / equity0.2×+0.1×

Current ratio4.4×-2.8×

Where this comes from

Reported directly by ASP Isotopes, Inc. in its filing.

Tagged under the XBRL concept aspi:SellerFinancedPortionOfInvestmentInEastCoastNuclearPharmacy.

The official record: ASP Isotopes, Inc.’s 10-K, filed April 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about ASP Isotopes, Inc.'s seller financed portion of investment in east coast nuclear pharmacy.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ASP Isotopes, Inc.'s seller financed portion of investment in east coast nuclear pharmacy?: ASP Isotopes, Inc. (ASPI) reported seller financed portion of investment in east coast nuclear pharmacy of $125K in Q4 2025.
What does seller financed portion of investment in east coast nuclear pharmacy mean?: This represents the portion of an investment acquisition cost that is deferred and financed directly by the seller rather than through external debt or cash. It indicates the company's ability to negotiate favorable payment terms for strategic acquisitions. This metric is useful for assessing liquidity management and the structure of capital deployment.